Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
Domain	PID_Shc-like	SHC1 SHC4 SHC2	1.19e-06	4	126	3	IPR006019
Domain	SH2	SHC1 SHC4 SLA SHC2 SOCS5 SOCS4 PLCG1	5.47e-06	101	126	7	PF00017
Domain	SH2	SHC1 SHC4 SLA SHC2 SOCS5 SOCS4 PLCG1	9.62e-06	110	126	7	SM00252
Domain	SH2	SHC1 SHC4 SLA SHC2 SOCS5 SOCS4 PLCG1	1.02e-05	111	126	7	PS50001
Domain	SH2	SHC1 SHC4 SLA SHC2 SOCS5 SOCS4 PLCG1	1.08e-05	112	126	7	IPR000980
Domain	-	SHC1 SHC4 SLA SHC2 SOCS5 SOCS4 PLCG1	1.08e-05	112	126	7	3.30.505.10
Domain	SOCS	SOCS5 SOCS4	4.52e-05	2	126	2	PF12610
Domain	SOCS4/SOCS5_dom	SOCS5 SOCS4	4.52e-05	2	126	2	IPR022252
Domain	TRP_channel	TRPV1 TRPC7 TRPC6	4.75e-05	11	126	3	IPR004729
Domain	-	RANBP2 MYO7B SHC1 SHC4 PLEKHH1 MTMR7 MTMR4 SHC2 PLCG1 PLD1	3.22e-04	391	126	10	2.30.29.30
Domain	FATC	SMG1 ATR	4.46e-04	5	126	2	PF02260
Domain	ARM-like	SMG1 IPO7 ATR COPG2 XPO1 NCAPD2 STAG2 AGTPBP1	4.97e-04	270	126	8	IPR011989
Domain	PH_dom-like	RANBP2 MYO7B SHC1 SHC4 PLEKHH1 MTMR7 MTMR4 SHC2 PLCG1 PLD1	6.28e-04	426	126	10	IPR011993
Domain	TRP_2	TRPC7 TRPC6	6.65e-04	6	126	2	PF08344
Domain	TRP_dom	TRPC7 TRPC6	6.65e-04	6	126	2	IPR013555
Domain	FAT	SMG1 ATR	6.65e-04	6	126	2	PS51189
Domain	FATC	SMG1 ATR	6.65e-04	6	126	2	PS51190
Domain	FATC_dom	SMG1 ATR	6.65e-04	6	126	2	IPR003152
Domain	PIK_FAT	SMG1 ATR	6.65e-04	6	126	2	IPR014009
Domain	FATC	SMG1 ATR	6.65e-04	6	126	2	SM01343
Domain	PID	SHC1 SHC4 SHC2	8.68e-04	28	126	3	PF00640
Domain	TRPC_channel	TRPC7 TRPC6	9.27e-04	7	126	2	IPR002153
Domain	Ephrin	EFNA1 EFNA3	1.23e-03	8	126	2	PF00812
Domain	Ephrin_RBD	EFNA1 EFNA3	1.23e-03	8	126	2	IPR001799
Domain	Ephrin	EFNA1 EFNA3	1.23e-03	8	126	2	PD002533
Domain	Ephrin	EFNA1 EFNA3	1.23e-03	8	126	2	IPR031328
Domain	EPHRIN_RBD_1	EFNA1 EFNA3	1.23e-03	8	126	2	PS01299
Domain	Ephrin_CS	EFNA1 EFNA3	1.23e-03	8	126	2	IPR019765
Domain	EPHRIN_RBD_2	EFNA1 EFNA3	1.23e-03	8	126	2	PS51551
Domain	CH	CFAP47 SYNE1 LRCH1 DST	1.28e-03	70	126	4	PF00307
Domain	HEAT_REPEAT	SMG1 ATR COPG2 XPO1	1.28e-03	70	126	4	PS50077
Domain	PID	SHC1 SHC4 SHC2	1.29e-03	32	126	3	PS01179
Domain	-	CFAP47 SYNE1 LRCH1 DST	1.35e-03	71	126	4	1.10.418.10
Domain	CH	CFAP47 SYNE1 LRCH1 DST	1.50e-03	73	126	4	PS50021
Domain	MYTH4	MYO7B PLEKHH1	1.58e-03	9	126	2	PS51016
Domain	MyTH4	MYO7B PLEKHH1	1.58e-03	9	126	2	SM00139
Domain	MyTH4_dom	MYO7B PLEKHH1	1.58e-03	9	126	2	IPR000857
Domain	MyTH4	MYO7B PLEKHH1	1.58e-03	9	126	2	PF00784
Domain	CH-domain	CFAP47 SYNE1 LRCH1 DST	1.66e-03	75	126	4	IPR001715
Domain	ARM-type_fold	SMG1 IPO7 ATR COPG2 XPO1 NCAPD2 STAG2 AGTPBP1	2.13e-03	339	126	8	IPR016024
Domain	PKD_channel	PKD1 MCOLN3	2.39e-03	11	126	2	PF08016
Domain	PKD1_2_channel	PKD1 MCOLN3	2.39e-03	11	126	2	IPR013122
Domain	PTB	SHC1 SHC4 SHC2	2.47e-03	40	126	3	SM00462
Domain	PTB/PI_dom	SHC1 SHC4 SHC2	2.65e-03	41	126	3	IPR006020
Domain	Myotubularin-like_Pase_dom	MTMR7 MTMR4	3.90e-03	14	126	2	IPR010569
Domain	IMPORTIN_B_NT	IPO7 XPO1	3.90e-03	14	126	2	PS50166
Domain	-	EFNA1 EFNA3	3.90e-03	14	126	2	2.60.40.420
Domain	PPASE_MYOTUBULARIN	MTMR7 MTMR4	3.90e-03	14	126	2	PS51339
Domain	Myotubularin_fam	MTMR7 MTMR4	3.90e-03	14	126	2	IPR030564
Domain	Myotub-related	MTMR7 MTMR4	3.90e-03	14	126	2	PF06602
Domain	-	REXO5 POLA1 PIWIL2	3.92e-03	47	126	3	3.30.420.10
Domain	-	IPO7 ATR COPG2 XPO1 NCAPD2 AGTPBP1	3.98e-03	222	126	6	1.25.10.10
Domain	Clathrin/coatomer_adapt-like_N	COPG2 NCAPD2	4.48e-03	15	126	2	IPR002553
Domain	PI3/4_kinase_CS	SMG1 ATR	4.48e-03	15	126	2	IPR018936
Domain	Adaptin_N	COPG2 NCAPD2	4.48e-03	15	126	2	PF01602
Domain	IBN_N	IPO7 XPO1	4.48e-03	15	126	2	PF03810
Domain	-	SMG1 ATR	5.09e-03	16	126	2	1.10.1070.11
Domain	IBN_N	IPO7 XPO1	5.09e-03	16	126	2	SM00913
Domain	PI3Kc	SMG1 ATR	5.09e-03	16	126	2	SM00146
Domain	Quinoprotein_ADH-like_supfam	WDR6 WDR87 CFAP57	5.49e-03	53	126	3	IPR011047
Domain	Importin-beta_N	IPO7 XPO1	5.75e-03	17	126	2	IPR001494
Domain	PI3_PI4_kinase	SMG1 ATR	6.44e-03	18	126	2	PF00454
Domain	PI3_4_KINASE_1	SMG1 ATR	6.44e-03	18	126	2	PS00915
Domain	PI3_4_KINASE_2	SMG1 ATR	6.44e-03	18	126	2	PS00916
Domain	PI3/4_kinase_cat_dom	SMG1 ATR	6.44e-03	18	126	2	IPR000403
Domain	PI3_4_KINASE_3	SMG1 ATR	6.44e-03	18	126	2	PS50290
Pathway	REACTOME_SIGNALLING_TO_ERKS	MAPKAPK2 SHC1 SHC2 MAP2K1 MAP2K2	1.05e-06	26	102	5	MM14716
Pathway	REACTOME_SIGNALLING_TO_ERKS	MAPKAPK2 SHC1 SHC2 MAP2K1 MAP2K2	4.23e-06	34	102	5	M13881
Pathway	KEGG_GLIOMA	SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	7.24e-06	65	102	6	M1835
Pathway	REACTOME_SIGNALING_BY_NTRKS	MAPKAPK2 SHC1 SHC2 PLCG1 MAP2K1 MAP2K2	1.66e-05	75	102	6	MM14652
Pathway	KEGG_VEGF_SIGNALING_PATHWAY	MAPKAPK2 SHC2 PLCG1 MAP2K1 MAP2K2 NOS3	1.80e-05	76	102	6	M1749
Pathway	WP_EGFR_TYROSINE_KINASE_INHIBITOR_RESISTANCE	SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	3.19e-05	84	102	6	M39839
Pathway	BIOCARTA_PYK2_PATHWAY	SHC1 PLCG1 MAP2K1 MAP2K2	3.42e-05	26	102	4	MM1431
Pathway	KEGG_NEUROTROPHIN_SIGNALING_PATHWAY	MAPKAPK2 SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	3.52e-05	126	102	7	M16763
Pathway	KEGG_ERBB_SIGNALING_PATHWAY	SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	3.89e-05	87	102	6	M12467
Pathway	BIOCARTA_PYK2_PATHWAY	SHC1 PLCG1 MAP2K1 MAP2K2	3.99e-05	27	102	4	M7739
Pathway	REACTOME_ROLE_OF_SECOND_MESSENGERS_IN_NETRIN_1_SIGNALING	TRPC7 TRPC6 PLCG1	4.25e-05	10	102	3	M27330
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_PATHWAY_ADAPTOR_PROTEINS	SHC1 SHC4 SHC2	4.25e-05	10	102	3	M47930
Pathway	REACTOME_TRP_CHANNELS	TRPV1 TRPC7 TRPC6 MCOLN3	4.63e-05	28	102	4	MM14943
Pathway	REACTOME_TRP_CHANNELS	TRPV1 TRPC7 TRPC6 MCOLN3	4.63e-05	28	102	4	M27241
Pathway	WP_ERBB_SIGNALING	SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	5.34e-05	92	102	6	M39715
Pathway	BIOCARTA_BIOPEPTIDES_PATHWAY	SHC1 PLCG1 MAP2K1 MAP2K2	5.34e-05	29	102	4	MM1356
Pathway	BIOCARTA_BIOPEPTIDES_PATHWAY	SHC1 PLCG1 MAP2K1 MAP2K2	5.34e-05	29	102	4	M13494
Pathway	REACTOME_SIGNALLING_TO_RAS	MAPKAPK2 SHC1 SHC2	7.72e-05	12	102	3	MM14657
Pathway	WP_BDNFTRKB_SIGNALING	TRPC6 SHC1 PLCG1 MAP2K1	9.00e-05	33	102	4	M39532
Pathway	REACTOME_SIGNALING_BY_NTRK1_TRKA	MAPKAPK2 SHC1 SHC2 MAP2K1 MAP2K2	9.05e-05	63	102	5	MM14714
Pathway	REACTOME_NERVOUS_SYSTEM_DEVELOPMENT	SHC1 EFNA1 EFNA3 ST8SIA2 PLCG1 MAP2K1 MAP2K2 EPHA10 PLXNB1	1.14e-04	261	102	9	MM15676
Pathway	WP_BREAST_CANCER_PATHWAY	ATR SHC1 SHC4 FZD8 SHC2 MAP2K1 MAP2K2	1.26e-04	154	102	7	M39739
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_PLCG_ERK_SIGNALING_PATHWAY	PLCG1 MAP2K1 MAP2K2	1.26e-04	14	102	3	M47383
Pathway	KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_PLCG_ERK_SIGNALING_PATHWAY	PLCG1 MAP2K1 MAP2K2	1.26e-04	14	102	3	M47384
Pathway	PID_VEGFR1_2_PATHWAY	MAPKAPK2 PLCG1 MAP2K1 MAP2K2 NOS3	1.40e-04	69	102	5	M237
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_PLCG_ERK_SIGNALING_PATHWAY	PLCG1 MAP2K1 MAP2K2	1.57e-04	15	102	3	M47382
Pathway	WP_KIT_RECEPTOR_SIGNALING_PATHWAY	SHC1 SOCS5 SOCS4 PLCG1 MAP2K1	1.60e-04	71	102	5	MM15947
Pathway	KEGG_CHRONIC_MYELOID_LEUKEMIA	SHC1 SHC4 SHC2 MAP2K1 MAP2K2	1.83e-04	73	102	5	M321
Pathway	WP_MAPK_PATHWAY_IN_CONGENITAL_THYROID_CANCER	SHC1 MAP2K1 MAP2K2	1.92e-04	16	102	3	M39882
Pathway	WP_LEPTIN_SIGNALING	SHC1 PLCG1 MAP2K1 MAP2K2 NOS3	2.21e-04	76	102	5	M39491
Pathway	SA_TRKA_RECEPTOR	SHC1 MAP2K1 MAP2K2	2.32e-04	17	102	3	M18895
Pathway	REACTOME_SIGNALING_BY_ALK	SHC1 PTPRZ1 PLCG1	2.32e-04	17	102	3	MM14790
Pathway	REACTOME_RND2_GTPASE_CYCLE	PRAG1 TXNL1 DST WDR6	2.57e-04	43	102	4	M41827
Pathway	REACTOME_EPHA_MEDIATED_GROWTH_CONE_COLLAPSE	EFNA1 EFNA3 EPHA10	2.77e-04	18	102	3	MM15023
Pathway	REACTOME_RND2_GTPASE_CYCLE	PRAG1 TXNL1 DST WDR6	2.81e-04	44	102	4	MM15678
Pathway	WP_SEROTONIN_RECEPTOR_467_AND_NR3C_SIGNALING	MAPKAPK2 MAP2K1 MAP2K2	3.28e-04	19	102	3	M39358
Pathway	KEGG_MEDICUS_REFERENCE_CXCL12_CXCR4_PKC_ERK_SIGNALING_PATHAWAY	PLCG1 MAP2K1 MAP2K2	3.28e-04	19	102	3	M47596
Pathway	BIOCARTA_EPO_PATHWAY	SHC1 PLCG1 MAP2K1	3.28e-04	19	102	3	M12836
Pathway	WP_RAS_SIGNALING	SHC1 SHC4 SHC2 PLCG1 PLD1 MAP2K1 MAP2K2	3.74e-04	184	102	7	M39764
Pathway	BIOCARTA_EPO_PATHWAY	SHC1 PLCG1 MAP2K1	3.83e-04	20	102	3	MM1389
Pathway	REACTOME_SIGNALLING_TO_RAS	MAPKAPK2 SHC1 SHC2	3.83e-04	20	102	3	M12256
Pathway	WP_SEROTONIN_RECEPTOR_2_AND_ELKSRFGATA4_SIGNALING	MAPKAPK2 MAP2K1 MAP2K2	3.83e-04	20	102	3	M39485
Pathway	BIOCARTA_NGF_PATHWAY	SHC1 PLCG1 MAP2K1	3.83e-04	20	102	3	M7860
Pathway	REACTOME_SIGNALING_BY_NTRKS	MAPKAPK2 SHC1 SHC2 PLCG1 MAP2K1 MAP2K2	4.21e-04	134	102	6	M3574
Pathway	KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY	SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	4.73e-04	137	102	6	M5669
Pathway	KEGG_INSULIN_SIGNALING_PATHWAY	SHC1 SHC4 SHC2 SOCS4 MAP2K1 MAP2K2	4.73e-04	137	102	6	M18155
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_BRAF_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	5.11e-04	5	102	2	M49016
Pathway	BIOCARTA_NGF_PATHWAY	SHC1 PLCG1 MAP2K1	5.12e-04	22	102	3	MM1440
Pathway	WP_BRAINDERIVED_NEUROTROPHIC_FACTOR_BDNF_SIGNALING	SHC1 SHC4 SHC2 PLCG1 MAP2K1 MAP2K2	6.16e-04	144	102	6	M39691
Pathway	WP_IL1_SIGNALING	MAPKAPK2 PLCG1 MAP2K1 MAP2K2	6.64e-04	55	102	4	M39346
Pathway	PID_IL2_1PATHWAY	MAPKAPK2 SHC1 MAP2K1 MAP2K2	6.64e-04	55	102	4	M122
Pathway	BIOCARTA_TPO_PATHWAY	SHC1 PLCG1 MAP2K1	6.67e-04	24	102	3	M11520
Pathway	BIOCARTA_TPO_PATHWAY	SHC1 PLCG1 MAP2K1	7.53e-04	25	102	3	MM1519
Pathway	PID_SHP2_PATHWAY	SHC1 MAP2K1 MAP2K2 NOS3	7.60e-04	57	102	4	M100
Pathway	REACTOME_NEGATIVE_FEEDBACK_REGULATION_OF_MAPK_PATHWAY	MAP2K1 MAP2K2	7.63e-04	6	102	2	M27559
Pathway	REACTOME_NEGATIVE_FEEDBACK_REGULATION_OF_MAPK_PATHWAY	MAP2K1 MAP2K2	7.63e-04	6	102	2	MM15273
Pathway	KEGG_MEDICUS_PATHOGEN_YERSINIA_YOPP_J_TO_TLR2_4_MAPK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	7.63e-04	6	102	2	M47636
Pathway	WP_IL6_SIGNALING_PATHWAY	MAPKAPK2 SHC1 PLCG1 MAP2K1 MAP2K2	7.85e-04	100	102	5	MM15826
Pathway	BIOCARTA_AT1R_PATHWAY	SHC1 MAP2K1 MAP2K2	8.47e-04	26	102	3	MM1346
Pathway	PID_VEGFR1_PATHWAY	SHC2 PLCG1 NOS3	8.47e-04	26	102	3	M226
Pathway	WP_EPO_RECEPTOR_SIGNALING	SHC1 MAP2K1 MAP2K2	8.47e-04	26	102	3	M39687
Pathway	WP_EPO_RECEPTOR_SIGNALING	SHC1 MAP2K1 MAP2K2	8.47e-04	26	102	3	MM15896
Pathway	WP_KIT_RECEPTOR_SIGNALING	SHC1 PLCG1 MAP2K1 MAP2K2	8.66e-04	59	102	4	M39350
Pathway	PID_FCER1_PATHWAY	SHC1 PLCG1 MAP2K1 MAP2K2	9.23e-04	60	102	4	M7
Pathway	BIOCARTA_AT1R_PATHWAY	SHC1 MAP2K1 MAP2K2	9.48e-04	27	102	3	M14899
Pathway	BIOCARTA_ERK_PATHWAY	SHC1 MAP2K1 MAP2K2	9.48e-04	27	102	3	M287
Pathway	BIOCARTA_GH_PATHWAY	SHC1 PLCG1 MAP2K1	9.48e-04	27	102	3	M9043
Pathway	BIOCARTA_EGF_PATHWAY	SHC1 PLCG1 MAP2K1	9.48e-04	27	102	3	M1909
Pathway	BIOCARTA_VEGF_PATHWAY	SHC1 PLCG1 NOS3	9.48e-04	27	102	3	M12975
Pathway	PID_TRKR_PATHWAY	SHC1 SHC2 PLCG1 MAP2K1	9.83e-04	61	102	4	M187
Pathway	BIOCARTA_EGF_PATHWAY	SHC1 PLCG1 MAP2K1	1.06e-03	28	102	3	MM1386
Pathway	BIOCARTA_ERK_PATHWAY	SHC1 MAP2K1 MAP2K2	1.06e-03	28	102	3	MM1391
Pathway	BIOCARTA_PDGF_PATHWAY	SHC1 PLCG1 MAP2K1	1.06e-03	28	102	3	M2529
Pathway	PID_ENDOTHELIN_PATHWAY	TRPC6 GNA12 MAP2K1 MAP2K2	1.11e-03	63	102	4	M8
Pathway	WP_EGFEGFR_SIGNALING	SHC1 PLCG1 PLD1 MAP2K1 MAP2K2 NOS3	1.14e-03	162	102	6	M39334
Pathway	WP_PDGFRBETA_PATHWAY	SHC1 PLCG1 MAP2K1	1.17e-03	29	102	3	M39616
Pathway	REACTOME_EPHA_MEDIATED_GROWTH_CONE_COLLAPSE	EFNA1 EFNA3 EPHA10	1.17e-03	29	102	3	M27309
Pathway	BIOCARTA_PDGF_PATHWAY	SHC1 PLCG1 MAP2K1	1.17e-03	29	102	3	MM1452
Pathway	WP_ANDROGEN_RECEPTOR_NETWORK_IN_PROSTATE_CANCER	ATR MSH6 SMARCD1 MAP2K1 MAP2K2	1.21e-03	110	102	5	M48043
Pathway	REACTOME_SIGNALING_BY_ALK	SHC1 PTPRZ1 PLCG1	1.30e-03	30	102	3	M42517
Pathway	WP_PHYSICOCHEMICAL_FEATURES_AND_TOXICITYASSOCIATED_PATHWAYS	SHC1 FZD8 PLCG1 MAP2K1	1.32e-03	66	102	4	M39642
Pathway	PID_AR_NONGENOMIC_PATHWAY	PLCG1 MAP2K1 MAP2K2	1.43e-03	31	102	3	M213
Pathway	BIOCARTA_BCR_PATHWAY	SHC1 PLCG1 MAP2K1	1.57e-03	32	102	3	MM1355
Pathway	PID_NETRIN_PATHWAY	PLCG1 MAP2K1 MAP2K2	1.57e-03	32	102	3	M108
Pathway	PID_EPO_PATHWAY	TRPC6 SHC1 PLCG1	1.71e-03	33	102	3	M233
Pathway	BIOCARTA_BCR_PATHWAY	SHC1 PLCG1 MAP2K1	1.71e-03	33	102	3	M9494
Pathway	REACTOME_EXPORT_OF_VIRAL_RIBONUCLEOPROTEINS_FROM_NUCLEUS	RANBP2 XPO1 NUP155	1.71e-03	33	102	3	M27016
Pathway	BIOCARTA_GH_PATHWAY	SHC1 PLCG1 MAP2K1	1.71e-03	33	102	3	MM1404
Pathway	BIOCARTA_INTEGRIN_PATHWAY	SHC1 MAP2K1 MAP2K2	1.71e-03	33	102	3	MM1426
Pathway	WP_ETHANOL_METABOLISM_PRODUCTION_OF_ROS_BY_CYP2E1	MAP2K1 MAP2K2	1.81e-03	9	102	2	M39481
Pathway	BIOCARTA_INTEGRIN_PATHWAY	SHC1 MAP2K1 MAP2K2	1.87e-03	34	102	3	M3342
Pathway	PID_MAPK_TRK_PATHWAY	TRPV1 MAPKAPK2 MAP2K1	1.87e-03	34	102	3	M270
Pathway	REACTOME_EPH_EPHRIN_MEDIATED_REPULSION_OF_CELLS	EFNA1 EFNA3 EPHA10	1.87e-03	34	102	3	MM15025
Pathway	PID_EPHA_FWDPATHWAY	EFNA1 EFNA3 PLCG1	1.87e-03	34	102	3	M177
Pathway	PID_PI3K_PLC_TRK_PATHWAY	TRPV1 SHC1 PLCG1	2.21e-03	36	102	3	M271
Pathway	PID_GMCSF_PATHWAY	SHC1 MAP2K1 MAP2K2	2.21e-03	36	102	3	M22
Pathway	BIOCARTA_MAPK_PATHWAY	MAPKAPK2 SHC1 MAP2K1 MAP2K2	2.22e-03	76	102	4	MM1433
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KRAS_NRAS_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.25e-03	10	102	2	M47374
Pathway	KEGG_MEDICUS_VARIANT_HRAS_OVEREXPRESSION_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.25e-03	10	102	2	M47420
Pathway	WP_ETHANOL_METABOLISM_RESULTING_IN_PRODUCTION_OF_ROS_BY_CYP2E1	MAP2K1 MAP2K2	2.25e-03	10	102	2	MM15821
Pubmed	Tat protein from HIV-1 activates MAP kinase in granular neurons and glial cells from rat cerebellum.	SHC1 SHC2 MAP2K1 MAP2K2	6.27e-09	7	129	4	9325171
Pubmed	Nerve growth factor signaling, neuroprotection, and neural repair.	MAPKAPK2 SHC1 SHC2 MAP2K1 MAP2K2	4.01e-08	26	129	5	11520933
Pubmed	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.	PCYT1A RANBP2 IPO7 ATR POLA1 SMARCAD1 XPO1 GPKOW CDC45 TXNL1 MSH6 NUP155 UBR5 PSMG1 NCAPD2 SMARCD1 STAG2 MED13	4.20e-08	1014	129	18	32416067
Pubmed	A quantitative analysis of the spatiotemporal pattern of transient receptor potential gene expression in the developing mouse cochlea.	TRPV1 TRPC7 TRPC6 PKD1 MCOLN3	1.42e-07	33	129	5	19834762
Pubmed	Expression patterns of ShcD and Shc family adaptor proteins during mouse embryonic development.	SHC1 SHC4 SHC2	1.99e-07	4	129	3	21117147
Pubmed	Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactome.	SHC1 SHC4 SLA SHC2 SOCS5 PLCG1	3.22e-07	73	129	6	24728074
Pubmed	Comprehensive binary interaction mapping of SH2 domains via fluorescence polarization reveals novel functional diversification of ErbB receptors.	SHC1 SHC4 SLA SHC2 SOCS5 PLCG1	4.43e-07	77	129	6	22973453
Pubmed	The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells.	ATR SHC1 SHC2	4.96e-07	5	129	3	10749680
Pubmed	The ShcD signaling adaptor facilitates ligand-independent phosphorylation of the EGF receptor.	SHC1 SHC4 SHC2	4.96e-07	5	129	3	24430869
Pubmed	Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.	MAP2K1 MAP2K2 NOS3	4.96e-07	5	129	3	22465219
Pubmed	Developmental waves of mechanosensitivity acquisition in sensory neuron subtypes during embryonic development.	TRPV1 TRPC7 TRPC6 PKD1 MCOLN3	6.28e-07	44	129	5	19322198
Pubmed	Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis.	EFNA1 EFNA3 EPHA10	9.89e-07	6	129	3	15777695
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	RANBP2 IPO7 MYO1D POLA1 COPG2 XPO1 MSH6 DST NUP155 UBR5 WDR6 NCAPD2 STAG2	1.03e-06	653	129	13	22586326
Pubmed	A multi-factor trafficking site on the spliceosome remodeling enzyme BRR2 recruits C9ORF78 to regulate alternative splicing.	PCYT1A IPO7 CNOT10 MRPL37 COPG2 XPO1 GPKOW CDC45 MSH6 NUP155 WDR6 NCAPD2	1.28e-06	560	129	12	35241646
Pubmed	Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice.	RANBP2 IPO7 ATR SHC1 COPG2 SMARCAD1 MSH6 OTULIN NUP155 NCAPD2 MAP2K2 STAG2	1.91e-06	582	129	12	20467437
Pubmed	International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels.	TRPV1 TRPC7 TRPC6 MCOLN3	2.15e-06	25	129	4	16382100
Pubmed	Mapping the MOB proteins' proximity network reveals a unique interaction between human MOB3C and the RNase P complex.	RANBP2 COPG2 XPO1 LRCH1 MSH6 NUP155 UBR5 STON2 NCAPD2 SMARCD1	2.58e-06	399	129	10	37536630
Pubmed	An introduction to TRP channels.	TRPV1 TRPC7 TRPC6 MCOLN3	2.97e-06	27	129	4	16460286
Pubmed	A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling.	RANBP2 IPO7 SHC1 XPO1 CDC45 TXNL1 MSH6 SEPSECS MTMR7 MTMR4 NUP155 UBR5 WDR6 PLCG1 ZNF548	3.52e-06	974	129	15	28675297
Pubmed	Cellular subtype distribution and developmental regulation of TRPC channel members in the mouse dorsal root ganglion.	TRPV1 TRPC7 TRPC6	4.12e-06	9	129	3	17480026
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	RANBP2 IPO7 ATR MYO1D POLA1 SYNE1 MRPL37 SMARCAD1 XPO1 OGDH CDC45 MSH6 NUP155 WDR6 HPRT1 NCAPD2 PLCG1 STAG2	5.62e-06	1425	129	18	30948266
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	RANBP2 IPO7 MYO1D SHC1 COPG2 XPO1 MSH6 MTMR7 KMT2D MTMR4 NUP155 PTPRZ1 CRLF3 KLHL15 AGTPBP1	8.55e-06	1049	129	15	27880917
Pubmed	Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.	MAP2K1 MAP2K2	1.37e-05	2	129	2	9563949
Pubmed	Activation of transient receptor potential vanilloid 1 by dietary capsaicin delays the onset of stroke in stroke-prone spontaneously hypertensive rats.	TRPV1 NOS3	1.37e-05	2	129	2	21852608
Pubmed	Mitogen-activated protein kinase-activated protein kinase 2 mediates apoptosis during lung vascular permeability by regulating movement of cleaved caspase 3.	MAPKAPK2 MAP2K2	1.37e-05	2	129	2	24304496
Pubmed	Mek2 is dispensable for mouse growth and development.	MAP2K1 MAP2K2	1.37e-05	2	129	2	12832465
Pubmed	Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.	HPRT1 PKD1	1.37e-05	2	129	2	23064367
Pubmed	Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.	MAP2K1 MAP2K2	1.37e-05	2	129	2	19014680
Pubmed	Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.	MAP2K1 MAP2K2	1.37e-05	2	129	2	26625317
Pubmed	Identification of polycystin-1 and Gα12 binding regions necessary for regulation of apoptosis.	PKD1 GNA12	1.37e-05	2	129	2	20837139
Pubmed	Gα12 is required for renal cystogenesis induced by Pkd1 inactivation.	PKD1 GNA12	1.37e-05	2	129	2	27505895
Pubmed	Distinct cellular functions of MK2.	MAPKAPK2 MAP2K2	1.37e-05	2	129	2	12052889
Pubmed	Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation.	MAP2K1 MAP2K2	1.37e-05	2	129	2	21699731
Pubmed	Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia.	MAP2K1 MAP2K2	1.37e-05	2	129	2	17419998
Pubmed	MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.	MAP2K1 MAP2K2	1.37e-05	2	129	2	23735655
Pubmed	TRPC6 Deletion Enhances eNOS Expression and Reduces LPS-Induced Acute Lung Injury.	TRPC6 NOS3	1.37e-05	2	129	2	38069081
Pubmed	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.	MAP2K1 MAP2K2	1.37e-05	2	129	2	35069558
Pubmed	Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry.	XPO1 AGTPBP1	1.37e-05	2	129	2	23242554
Pubmed	The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.	MAP2K1 MAP2K2	1.37e-05	2	129	2	21527500
Pubmed	Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.	MAP2K1 MAP2K2	1.37e-05	2	129	2	19383924
Pubmed	Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1.	TRPV1 NOS3	1.37e-05	2	129	2	21493704
Pubmed	MEK1 and MEK2, different regulators of the G1/S transition.	MAP2K1 MAP2K2	1.37e-05	2	129	2	15284233
Pubmed	Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.	MAP2K1 MAP2K2	1.37e-05	2	129	2	19156172
Pubmed	The N-terminal domains of SOCS proteins: a conserved region in the disordered N-termini of SOCS4 and 5.	SOCS5 SOCS4	1.37e-05	2	129	2	22423360
Pubmed	Molecular determinants for cardiovascular TRPC6 channel regulation by Ca2+/calmodulin-dependent kinase II.	TRPC7 TRPC6	1.37e-05	2	129	2	23529130
Pubmed	p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2.	MAP2K1 MAP2K2	1.37e-05	2	129	2	12839928
Pubmed	Ephrin-A1 is up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS.	EFNA1 NOS3	1.37e-05	2	129	2	24040255
Pubmed	MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.	MAP2K1 MAP2K2	1.37e-05	2	129	2	16957420
Pubmed	T cell adhesion primes antigen receptor-induced calcium responses through a transient rise in adenosine 3',5'-cyclic monophosphate.	MAP2K1 MAP2K2	1.37e-05	2	129	2	19144315
Pubmed	Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.	MAP2K1 MAP2K2	1.37e-05	2	129	2	19500021
Pubmed	Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.	MAP2K1 MAP2K2	1.37e-05	2	129	2	22197931
Pubmed	PLC-mediated PI(4,5)P2 hydrolysis regulates activation and inactivation of TRPC6/7 channels.	TRPC7 TRPC6	1.37e-05	2	129	2	24470487
Pubmed	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.	MAP2K1 MAP2K2	1.37e-05	2	129	2	27956260
Pubmed	Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.	MAP2K1 MAP2K2	1.37e-05	2	129	2	17981815
Pubmed	Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells.	MAP2K1 MAP2K2	1.37e-05	2	129	2	28746311
Pubmed	Intrinsically active MEK variants are differentially regulated by proteinases and phosphatases.	MAP2K1 MAP2K2	1.37e-05	2	129	2	30087384
Pubmed	Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.	MAP2K1 MAP2K2	1.37e-05	2	129	2	22833572
Pubmed	ERK1/2 can feedback-regulate cellular MEK1/2 levels.	MAP2K1 MAP2K2	1.37e-05	2	129	2	26163823
Pubmed	Omics profiling identifies the regulatory functions of the MAPK/ERK pathway in nephron progenitor metabolism.	MAP2K1 MAP2K2	1.37e-05	2	129	2	36189831
Pubmed	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	MAP2K1 MAP2K2	1.37e-05	2	129	2	22805292
Pubmed	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.	MAP2K1 MAP2K2	1.37e-05	2	129	2	22805291
Pubmed	MAPK-activated protein kinase 2 differentially regulates plasmodium falciparum glycosylphosphatidylinositol-induced production of tumor necrosis factor-{alpha} and interleukin-12 in macrophages.	MAPKAPK2 MAP2K2	1.37e-05	2	129	2	19359247
Pubmed	Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway.	MAP2K1 MAP2K2	1.37e-05	2	129	2	35975983
Pubmed	Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc.	MAP2K1 MAP2K2	1.37e-05	2	129	2	16162927
Pubmed	Importin 7 and Nup358 promote nuclear import of the protein component of human telomerase.	RANBP2 IPO7	1.37e-05	2	129	2	24586428
Pubmed	Regulation of intracellular MEK1/2 translocation in mouse oocytes: cytoplasmic dynein/dynactin-mediated poleward transport and cyclin B degradation-dependent release from spindle poles.	MAP2K1 MAP2K2	1.37e-05	2	129	2	17507801
Pubmed	Activation of two isoforms of mitogen-activated protein kinase kinase in response to epidermal growth factor and nerve growth factor.	MAP2K1 MAP2K2	1.37e-05	2	129	2	8529659
Pubmed	Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product.	MAP2K1 MAP2K2	1.37e-05	2	129	2	1381507
Pubmed	[Mek1 and Mek2 functions in the formation of the blood placental barrier].	MAP2K1 MAP2K2	1.37e-05	2	129	2	22549869
Pubmed	The ERK1/2 pathway regulates testosterone synthesis by coordinately regulating the expression of steroidogenic genes in Leydig cells.	MAP2K1 MAP2K2	1.37e-05	2	129	2	23480967
Pubmed	MK2 signaling: lessons on tissue specificity in modulation of inflammation.	MAPKAPK2 MAP2K2	1.37e-05	2	129	2	20081887
Pubmed	Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.	MAP2K1 MAP2K2	1.37e-05	2	129	2	23237773
Pubmed	Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis.	IPO7 XPO1	1.37e-05	2	129	2	22284678
Pubmed	Cisplatin inhibits MEK1/2.	MAP2K1 MAP2K2	1.37e-05	2	129	2	26155939
Pubmed	Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.	MAP2K1 MAP2K2	1.37e-05	2	129	2	19198628
Pubmed	Characterization of the proline-rich region of mouse MAPKAP kinase 2: influence on catalytic properties and binding to the c-abl SH3 domain in vitro.	MAPKAPK2 MAP2K2	1.37e-05	2	129	2	8093038
Pubmed	Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.	MAP2K1 MAP2K2	1.37e-05	2	129	2	15979847
Pubmed	WDR87 interacts with CFAP47 protein in the middle piece of spermatozoa flagella to participate in sperm tail assembly.	CFAP47 WDR87	1.37e-05	2	129	2	36571501
Pubmed	ERK (MAPK) does not phosphorylate tau under physiological conditions in vivo or in vitro.	MAP2K1 MAP2K2	1.37e-05	2	129	2	25491074
Pubmed	Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2.	MAP2K1 MAP2K2	1.37e-05	2	129	2	20172001
Pubmed	Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.	MAP2K1 MAP2K2	1.37e-05	2	129	2	10828601
Pubmed	Implication of MEK1 and MEK2 in the establishment of the blood-placenta barrier during placentogenesis in mouse.	MAP2K1 MAP2K2	1.37e-05	2	129	2	22561024
Pubmed	Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.	MAP2K1 MAP2K2	1.37e-05	2	129	2	15543157
Pubmed	Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.	TET2 KMT2D	1.37e-05	2	129	2	31311407
Pubmed	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	MAP2K1 MAP2K2	1.37e-05	2	129	2	18390968
Pubmed	Importin-β and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function.	RANBP2 XPO1	1.37e-05	2	129	2	28600321
Pubmed	Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.	SHC1 SOCS5 SOCS4	1.39e-05	13	129	3	23990909
Pubmed	Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma.	IPO7 MYO1D COPG2 XPO1 MSH6 KCTD5 WDR6 HPRT1 MAP2K1	1.39e-05	383	129	9	29331416
Pubmed	Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2.	ATR COPG2 XPO1 MSH6 UBR5	1.88e-05	87	129	5	17148452
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	SMG1 THSD7A SYNE1 LRCH1 DST ALMS1 UBR5	2.21e-05	225	129	7	12168954
Pubmed	Aire's partners in the molecular control of immunological tolerance.	RANBP2 IPO7 XPO1 MSH6	2.39e-05	45	129	4	20085707
Pubmed	Systematic identification of factors for provirus silencing in embryonic stem cells.	RANBP2 IPO7 SMARCAD1 MSH6 UBR5 SMARCD1	2.39e-05	153	129	6	26365490
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	SMG1 IPO7 MYO1D MRPL37 GPKOW PLEKHH1 RAD51AP2 KMT2D SMARCD1 MAP2K2 STAG2	2.74e-05	638	129	11	31182584
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	TET2 RANBP2 COPG2 TXNL1 KMT2D DST ALMS1 UBR5 WDR6	2.76e-05	418	129	9	34709266
Pubmed	TrkB-dependent EphrinA reverse signaling regulates callosal axon fasciculate growth downstream of Neurod2/6.	EFNA1 EFNA3 PLCG1 PLXNB1	2.85e-05	47	129	4	35462405
Pubmed	The Catalytically Inactive Mutation of the Ubiquitin-Conjugating Enzyme CDC34 Affects its Stability and Cell Proliferation.	RANBP2 XPO1 MSH6 NUP155 WDR6 NCAPD2 PLCG1	3.08e-05	237	129	7	29564676
Pubmed	Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	MYO1D SYNE1 DST NUP155 SACS	3.87e-05	101	129	5	9872452
Pubmed	Monitoring protein-protein interactions in mammalian cells by trans-SUMOylation.	MAPKAPK2 MAP2K1 MAP2K2	3.91e-05	18	129	3	21675959
Pubmed	Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector.	MAP2K1 MAP2K2	4.09e-05	3	129	2	10489373
Pubmed	The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1.	EFNA1 DST	4.09e-05	3	129	2	7670468
Interaction	GAREM1 interactions	SHC1 SHC4 XPO1 EFNA1 PLCG1	5.66e-07	27	123	5	int:GAREM1
Cytoband	17q22-q23	MTMR4 MED13	1.17e-04	6	129	2	17q22-q23
GeneFamily	SH2 domain containing	SHC1 SHC4 SLA SHC2 SOCS5 SOCS4 PLCG1	4.38e-07	101	84	7	741
GeneFamily	Transient receptor potential cation channels	TRPV1 TRPC7 TRPC6 MCOLN3	8.15e-06	28	84	4	249
GeneFamily	Mitogen-activated protein kinase kinases	MAP2K1 MAP2K2	4.41e-04	7	84	2	653
GeneFamily	Ephrins	EFNA1 EFNA3	5.86e-04	8	84	2	546
GeneFamily	SH2 domain containing\|Suppressors of cytokine signaling	SOCS5 SOCS4	5.86e-04	8	84	2	764
GeneFamily	Myotubularins\|Phosphoinositide phosphatases	MTMR7 MTMR4	2.15e-03	15	84	2	903
Coexpression	GSE27786_BCELL_VS_NKTCELL_UP	MMS22L LRCH1 CCNF RSBN1 MSH6 BST1 MED13 AGTPBP1	6.16e-06	200	127	8	M4808
Coexpression	HE_LIM_SUN_FETAL_LUNG_C5_LARGE_PRE_B_CELL	MMS22L REXO5 IPO7 DCPS POLA1 CNOT10 TTC39C COPG2 XPO1 CDC45 CCNF TRMU MSH6 OTULIN NUP155 PSMG1 HPRT1 NCAPD2 SMARCD1 MAP2K2	8.97e-06	1363	127	20	M45782
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	TET2 SMG1 CHDH TBCK NCAPD2 SMARCD1 MED13	2.86e-05	180	127	7	M8239
Coexpression	HE_LIM_SUN_FETAL_LUNG_C4_CYCLING_T_CELL	MMS22L POLA1 CNOT10 BACH2 XPO1 NEMP2 CDC45 CCNF MSH6 NUP155 ALMS1 WDR6 PSMG1 NCAPD2 MED13	5.11e-05	939	127	15	M45768
Coexpression	GSE14308_TH1_VS_TH17_DN	SMG1 ZNF560 LRCH1 KMT2D UBR5 CRLF3 PKD1	5.59e-05	200	127	7	M3374
Coexpression	GSE17721_CTRL_VS_GARDIQUIMOD_8H_BMDC_DN	RANBP2 MAPKAPK2 TTC39C KCNE1 CRLF3 PLCG1 OSGIN2	5.59e-05	200	127	7	M3790
Coexpression	GSE6259_DEC205_POS_DC_VS_CD4_TCELL_DN	MRPL37 NUP155 SACS PKD1 PLCG1 PLD1 MAP2K2	5.59e-05	200	127	7	M6774
Coexpression	ABRAMSON_INTERACT_WITH_AIRE	RANBP2 IPO7 XPO1 MSH6	6.14e-05	44	127	4	M2536
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	RANBP2 IPO7 ATR XPO1 RSBN1 MSH6 DST SACS UBR5 SOCS5 UGCG MAP2K1 STAG2 MED13	7.19e-05	856	127	14	M4500
CoexpressionAtlas	dev gonad_e11.5_F_PrimGermCell_Oct_k-means-cluster#3_top-relative-expression-ranked_1000	MMS22L POLA1 PIWIL2 CDC45 CCNF MSH6 MTMR7 UBR5 CRLF3 NCAPD2 OSGIN2 PRMT7	1.76e-05	463	124	12	gudmap_dev gonad_e11.5_F_PrimGermCell_Oct_k3_1000
ToppCell	pdx-Tumor_cells-T1\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	MMS22L POLA1 XPO1 CDC45 CCNF CRLF3 NCAPD2	1.39e-06	190	129	7	d06ee5f89f1cec8db6897fe3b2a890a07cd3697b
ToppCell	Sepsis-Int-URO-Lymphocyte-T/NK-dn_T\|Int-URO / Disease, condition lineage and cell class	POLA1 MRPL37 LRCH1 UBR5 TBCK GNA12 DTHD1	1.95e-06	200	129	7	020439d9e70fff7246650ab0e9105236688c3ec3
ToppCell	facs\|World / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IPO7 CYP20A1 COPG2 EFNA3 GNA12 PLCG1	1.10e-05	172	129	6	a2d0a64ebf09d219a07d6bbad1056bad6d46b9be
ToppCell	368C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	COPG2 CDC45 CCNF SACS KLHL15 AGTPBP1	1.14e-05	173	129	6	20889aa85e36ad3bafdb91b91e43964493c949f9
ToppCell	368C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	COPG2 CDC45 CCNF SACS KLHL15 AGTPBP1	1.14e-05	173	129	6	46e601b7938b1dd0aa3df7aa056c4bd07b1620c1
ToppCell	CV-Severe-7\|Severe / Virus stimulation, Condition and Cluster	SMG1 MMS22L CDC45 DST UBR5 TBCK	1.30e-05	177	129	6	82fdd6185b368f54f03de389427cbe3071d21a99
ToppCell	droplet-Heart-nan-3m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHLD2 COL16A1 CYP20A1 PTPRZ1 TBCK PLXNB1	1.43e-05	180	129	6	da723df348d7b8449bb1124f23fe6fa706412adb
ToppCell	droplet-Heart-nan-3m-Neuronal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHLD2 COL16A1 CYP20A1 PTPRZ1 TBCK PLXNB1	1.43e-05	180	129	6	5b146a94708b3c3610542a4d0925f3f7a2b19185
ToppCell	droplet-Heart-nan-3m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHLD2 COL16A1 CYP20A1 PTPRZ1 TBCK PLXNB1	1.43e-05	180	129	6	50758b1e7be2e43f83c10ab106900c067e61f5f7
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	MMS22L XPO1 KMT2D NUP155 KLHL15 AGTPBP1	1.67e-05	185	129	6	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	MMS22L XPO1 MSH6 NUP155 KLHL15 AGTPBP1	1.72e-05	186	129	6	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	droplet-Fat-SCAT-30m-Epithelial\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IPO7 POLA1 CHDH PKD1 STON2 PLXNB1	1.77e-05	187	129	6	5fada3c5a58c1890029ccbfff2608b33f8cd2df7
ToppCell	droplet-Fat-SCAT-30m-Epithelial-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IPO7 POLA1 CHDH PKD1 STON2 PLXNB1	1.77e-05	187	129	6	766e808138fc2cd623c2e6d57fcb5c7378da0e03
ToppCell	droplet-Fat-SCAT-30m-Epithelial-epithelial_cell\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IPO7 POLA1 CHDH PKD1 STON2 PLXNB1	1.77e-05	187	129	6	f49d06600060deeb2fc1b1da5b93496535f20104
ToppCell	IPF-Epithelial-Basal\|Epithelial / Disease state, Lineage and Cell class	BACH2 TRPC6 LRCH1 DST PTPRZ1 STON2	1.94e-05	190	129	6	4f15842b424eefadbfe451875e517cf70e29607f
ToppCell	10x3'2.3-week_14-16-Myeloid_DC-DC-pDC\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	DCPS MAPKAPK2 SLC12A3 KCTD5 UGCG STAMBPL1	2.12e-05	193	129	6	2c35aadc397e7e365c3daf8017ae1d3bd045f305
ToppCell	PSB-critical-LOC-Epithelial-Ciliated\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CFAP47 SYNE1 KCNE1 TEKT1 CFAP57 DTHD1	2.38e-05	197	129	6	6865f4831eb23794fb88a8649d48d497bbae3f44
ToppCell	NS-moderate-d_0-4-Epithelial-Ciliated\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CFAP47 SYNE1 KCNE1 TEKT1 CFAP57 DTHD1	2.38e-05	197	129	6	71fea4aa6ce96c7693fa94792d08770622873850
Computational	Nucleotide metabolism.	POLA1 CDC45 NUP155 ALMS1 HPRT1 NCAPD2	5.98e-06	64	77	6	MODULE_337
Computational	Nuclear pore complex.	RANBP2 IPO7 XPO1	2.24e-04	17	77	3	MODULE_352
Disease	gastric adenocarcinoma (is_implicated_in)	XPO1 KMT2D UBR5	1.11e-05	11	122	3	DOID:3717 (is_implicated_in)
Disease	small intestine adenocarcinoma (is_implicated_in)	MAP2K1 MAP2K2	5.07e-05	3	122	2	DOID:4906 (is_implicated_in)
Disease	peritonsillar abscess	TET2 PRAG1 GNA12	5.38e-05	18	122	3	EFO_0007429
Disease	familial hyperlipidemia (biomarker_via_orthology)	SHC1 SMARCD1 NOS3	6.37e-05	19	122	3	DOID:1168 (biomarker_via_orthology)
Disease	Infiltrating duct carcinoma of female breast	SMG1 ATR EPHA10	8.69e-05	21	122	3	C3165106
Disease	breast cancer (is_marker_for)	TET2 AKR1A1 KMT2D PLCG1 MAP2K1 MAP2K2	1.24e-04	185	122	6	DOID:1612 (is_marker_for)
Disease	Sezary Syndrome	TET2 KMT2D PLCG1	1.88e-04	27	122	3	C0036920
Disease	corpus callosum mid-anterior volume measurement	TTC39C SLA SEPSECS	1.88e-04	27	122	3	EFO_0010297
Disease	Neoplasm of uncertain or unknown behavior of ovary	ATR MSH6 MAP2K1	2.33e-04	29	122	3	C0496920
Disease	Ovarian Carcinoma	ATR MSH6 MAP2K1	2.58e-04	30	122	3	C0029925
Disease	facial emotion recognition measurement	THSD7A MYO1D FAR2	4.10e-04	35	122	3	EFO_0008329
Disease	lung adenocarcinoma (is_marker_for)	AKR1A1 XPO1 PLCG1 MAP2K1	4.35e-04	85	122	4	DOID:3910 (is_marker_for)
Disease	centronuclear myopathy X-linked (implicated_via_orthology)	MTMR7 MTMR4	5.99e-04	9	122	2	DOID:0111225 (implicated_via_orthology)
Disease	RASopathy (implicated_via_orthology)	MAP2K1 MAP2K2	5.99e-04	9	122	2	DOID:0080690 (implicated_via_orthology)
Disease	migraine (is_implicated_in)	TRPV1 NOS3	5.99e-04	9	122	2	DOID:6364 (is_implicated_in)
Disease	Cutaneous Melanoma	MAP2K1 MAP2K2 STAG2	6.55e-04	41	122	3	C0151779
Disease	Adenocarcinoma of large intestine	MSH6 UBR5 TBCK MAP2K1	6.89e-04	96	122	4	C1319315
Disease	renal cell carcinoma	MYO7B PLD1 MAP2K1	7.04e-04	42	122	3	EFO_0000681
Disease	WNT1-inducible-signaling pathway protein 1 measurement	SLA SEPSECS	7.47e-04	10	122	2	EFO_0008321
Disease	corpus callosum volume measurement	TTC39C XPO1 SLA SEPSECS	8.03e-04	100	122	4	EFO_0010299
Disease	Noonan Syndrome 1	MAP2K1 MAP2K2	9.10e-04	11	122	2	C4551602
Disease	Turner Syndrome, Male	MAP2K1 MAP2K2	9.10e-04	11	122	2	C0041409
Disease	Female Pseudo-Turner Syndrome	MAP2K1 MAP2K2	9.10e-04	11	122	2	C1527404
Disease	cesarean section, intelligence	C6orf89 BACH2	1.09e-03	12	122	2	EFO_0004337, EFO_0009636
Disease	nicotine dependence (implicated_via_orthology)	TRPC7 TRPC6	1.09e-03	12	122	2	DOID:0050742 (implicated_via_orthology)
Disease	intracranial aneurysm (is_implicated_in)	KMT2D PKD1	1.09e-03	12	122	2	DOID:10941 (is_implicated_in)
Disease	Tourette syndrome	THSD7A EFNA1 CD276	1.17e-03	50	122	3	EFO_0004895
Disease	eosinophil count	TET2 DCPS ATR C6orf89 BACH2 SHC1 XPO1 SLA SEPSECS WDR6 PDE8B GNA12 PLD1 MAP2K2 EPHA10	1.25e-03	1488	122	15	EFO_0004842
Disease	Liver Cirrhosis, Experimental	TRPV1 RDH10 SLA PLEKHH1 FZD8 MTMR7 GPR68 UGCG NOS3 CD276	1.43e-03	774	122	10	C0023893
Disease	Pneumoconiosis	ATR PTPRZ1	1.49e-03	14	122	2	C0032273
Disease	Bagassosis	ATR PTPRZ1	1.49e-03	14	122	2	C0004681
Disease	Malignant Neoplasms	TRPV1 ATR MAP2K1 NOS3	2.00e-03	128	122	4	C0006826
Disease	Benign neoplasm of stomach	ATR UBR5	2.21e-03	17	122	2	C0153943
Disease	Vitiligo	BACH2 SLA	2.21e-03	17	122	2	C0042900
Disease	Neoplasm of uncertain or unknown behavior of stomach	ATR UBR5	2.21e-03	17	122	2	C0496905
Disease	Necrotizing Enterocolitis	AKR1A1 NOS3	2.21e-03	17	122	2	C0520459
Disease	Carcinoma in situ of stomach	ATR UBR5	2.21e-03	17	122	2	C0154060
Disease	oral squamous cell carcinoma (is_marker_for)	TET2 KMT2D PLCG1	2.29e-03	63	122	3	DOID:0050866 (is_marker_for)
Disease	essential hypertension (is_implicated_in)	SLC12A3 NOS3	2.48e-03	18	122	2	DOID:10825 (is_implicated_in)
Disease	Malignant neoplasm of endometrium	ATR MSH6	2.48e-03	18	122	2	C0007103
Disease	Carcinoma in situ of endometrium	ATR MSH6	2.48e-03	18	122	2	C0346191
Disease	breast carcinoma (is_marker_for)	MSH6 KMT2D PLCG1	2.61e-03	66	122	3	DOID:3459 (is_marker_for)
Disease	lung non-small cell carcinoma (is_implicated_in)	TET2 XPO1 KMT2D PLCG1	2.70e-03	139	122	4	DOID:3908 (is_implicated_in)
Disease	Bladder Neoplasm	TRPV1 GSTO2 KMT2D STAG2	2.77e-03	140	122	4	C0005695
Disease	Noonan-Like Syndrome With Loose Anagen Hair	MAP2K1 MAP2K2	2.77e-03	19	122	2	C3501846
Disease	Noonan syndrome-like disorder with loose anagen hair	MAP2K1 MAP2K2	2.77e-03	19	122	2	C1843181
Disease	Cardio-facio-cutaneous syndrome	MAP2K1 MAP2K2	2.77e-03	19	122	2	C1275081
Disease	Costello syndrome (disorder)	MAP2K1 MAP2K2	2.77e-03	19	122	2	C0587248
Disease	Malignant neoplasm of urinary bladder	TRPV1 GSTO2 KMT2D STAG2	2.84e-03	141	122	4	C0005684
Disease	stomach cancer (is_marker_for)	TET2 XPO1 KMT2D UBR5	2.91e-03	142	122	4	DOID:10534 (is_marker_for)
Disease	Stomach Carcinoma	ATR UBR5	3.38e-03	21	122	2	C0699791
Disease	esophagus squamous cell carcinoma (is_marker_for)	TET2 XPO1 KMT2D	3.61e-03	74	122	3	DOID:3748 (is_marker_for)
Disease	LEOPARD Syndrome	MAP2K1 MAP2K2	3.71e-03	22	122	2	C0175704
Disease	ATRIAL FIBRILLATION, FAMILIAL, 1 (disorder)	NUP155 KCNE1	3.71e-03	22	122	2	C1843687
Disease	unipolar depression, bipolar disorder, schizophrenia, sex interaction measurement	C6orf89 SHC4 GNA12	3.89e-03	76	122	3	EFO_0003761, EFO_0008343, MONDO_0004985, MONDO_0005090
Disease	Renal glomerular disease	TRPC6 SLC12A3	4.05e-03	23	122	2	C0268731
Disease	Glomerulopathy Assessment	TRPC6 SLC12A3	4.05e-03	23	122	2	C4521256

Protein segments in the cluster

Peptide	Gene	Start	Entry
NDYRPVKLLQCVDHS	BST1	261	Q10588
DIQSPEQIQALHRYC	BACH2	716	Q9BYV9
PAVQYCNLARDLHLE	ARHGEF37	316	A1IGU5
DLQQVHIYCDPELVL	COL16A1	221	Q07092
CPAQVELQSLYVDVH	FCRL4	441	Q96PJ5
YDKENRTPLIQAVHC	ANKRD20A5P	96	A0PJZ0
QRELFEQCKAPYVDH	ALMS1	2926	Q8TCU4
YSCLVRNPVLQQDAH	CD276	436	Q5ZPR3
HNPQQIYFRKDVLCE	AGTPBP1	866	Q9UPW5
VIENLECDPRHYQQR	DCPS	301	Q96C86
DHLEIYIQQACTRPI	CHDH	336	Q8NE62
IIRELQVLHECNSPY	MAP2K1	111	Q02750
IRELQVLHECNSPYI	MAP2K2	116	P36507
HIFEDLCNVRQQAIP	RAD51AP2	781	Q09MP3
EIHPEICRLYIQLQC	RGS7BP	116	Q6MZT1
REQVLKICANHYISP	RANBP2	1236	P49792
NVIDHYLCDVLPLLQ	OR8B4	171	Q96RC9
VCPNVHEKIRAIYAD	FAR2	71	Q96K12
HRDCAQYLREVAQPV	ESPNL	316	Q6ZVH7
EICYTAVVVPHILAN	OR10W1	61	Q8NGF6
ASQCPHIVRIVDVYE	MAPKAPK2	111	P49137
NLQTVRHQELPDCYD	MCOLN3	226	Q8TDD5
DAYRVCQILDIPFHQ	TRMU	56	O75648
QLIIPQERDCHDVYI	MTMR7	81	Q9Y216
VPQLFYCLHEIREEA	NLRP8	606	Q86W28
DDIICPQVVARYLSH	MMS22L	776	Q6ZRQ5
AGYILECENLLRQHV	DST	431	Q03001
DLHNCVAYIQEPRLL	CFAP57	1056	Q96MR6
EEHCLNPENTERIYQ	FSIP2	6406	Q5CZC0
VQHCRYVDEVVRNAP	PCYT1A	136	P49585
PCLTKHVLRENQDYV	PLXNB1	1851	O43157
YTIPEEDRHCIRENI	IPO7	81	O95373
ACYNELIQIEHGEVR	PDE8B	246	O95263
RIVYIAERHNCQYPE	NEMP2	81	A6NFY4
VLHIDPNVDYQFRVC	CRLF3	236	Q8IUI8
LAACREHQRAPEVYV	EEF2KMT	266	Q96G04
HIPVLETSQCQLIYE	GSTO2	71	Q9H4Y5
NLYHNCIRVIPEAIV	LRCH1	126	Q9Y2L9
PRENQVVELHYDAIC	GPKOW	451	Q92917
EHDRPIRTYQVCNVL	EPHA10	66	Q5JZY3
QDDYVLEVRHFQCPK	PTPRZ1	2176	P23471
PLCNHYAINDRLDAI	MSH6	781	P52701
PIIDLHECNIYDVKN	MRPL37	261	Q9BZE1
YLAQQIHPVVARICE	POLA1	1211	P09884
DPVLVCNSCYEHIQV	MTMR4	1161	Q9NYA4
CIHVLLIRYVENPSQ	NUP155	1326	O75694
LFCIPNHYAEDLERV	HPRT1	21	P00492
NLCDPHRYNILEDVA	NOS3	366	P29474
IVHDLPAAVLSYCQV	PSMG1	211	O95456
VVVDLVCYRRNGHNE	OGDH	501	Q02218
DDRHYNIPVRVCEET	OTULIN	336	Q96BN8
AVLCAYNSNIPVIHV	OSGIN2	316	Q9Y236
VVVACLFYEQHNRPR	FZD8	546	Q9H461
CYDRAIQLEPDQIIH	ATR	1721	Q13535
FVCDTHRPVNVVNVY	CDC45	96	O75419
QVCNLHFPDYVLDEV	KLHL15	586	Q96M94
VQVNVNDYLDIYCPH	EFNA3	51	P52797
LDVTVVYLNPEQHCC	CCNF	636	P41002
LVEHEEYQLCQPQSK	EFNA1	71	P20827
CEAVPHRATVYAQLV	PRMT7	171	Q9NVM4
RAVYAPQNIYCVHVD	GCNT3	151	O95395
PHRLEDVQRYLVQCF	GNA12	321	Q03113
QEALLPVVDYEHCSR	CELA3B	176	P08861
YEVLLCVQDHDDPAI	UGCG	81	Q16739
VIYEAASAIIHLPNC	COPG2	266	Q9UBF2
PSYVLQQLECRIINH	DTHD1	191	Q6ZMT9
QVPVKHVYRVLQCQE	KCTD5	151	Q9NXV2
CYVVENHLAIEQPNT	KCNE1	106	P15382
TPEKIEQLRYCQHVL	CYP20A1	316	Q6UW02
LEEEIQHFLCQYPEA	C6orf89	191	Q6UWU4
YTAEHQDIVCLLQPI	SACS	2246	Q9NZJ4
PEEYLHNCLIIVNTL	CFAP47	1821	Q6ZTR5
PEATVEHVYLRAQNC	PKD1	1256	P98161
AIDRLVAICNPLHYD	OR1L6	156	Q8NGR2
ENQHRVCFEHYPIQA	GPR68	166	Q15743
PRLTFQCLEDLVNHY	SLA	146	Q13239
CDNDIYFIPRNVIHQ	RSBN1	671	Q5VWQ0
ANVVILHDIDCNPYN	SMARCAD1	941	Q9H4L7
TQIDYIHCLVPDLLQ	SOCS5	361	O75159
PHEREFVICDKYLQQ	SMARCD1	331	Q96GM5
LDHVNQAQVYEVVPC	THSD7A	1076	Q9UPZ6
LQSVLEEIHCYEPQL	SYNE1	3216	Q8NF91
VFRCLPNDEVHNLIQ	PLD1	1001	Q13393
EVNHCLPEKIVVYRD	PIWIL2	801	Q8TC59
NHPEVYVRQSICNLL	SMG1	1831	Q96Q15
TQIDYVHCLVPDLLQ	SOCS4	266	Q8WXH5
RECVPTEYHEIQNQC	SHLD2	196	Q86V20
VIRCNLAPVQEYARD	ST8SIA2	181	Q92186
THRPNVELCRDVAQY	TEKT1	321	Q969V4
QRDIAYVVLCPENEA	MED13	1366	Q9UHV7
NPIIYCLRNHEVKAA	OR6Y1	291	Q8NGX8
EEEILPHCNLQVFTY	RDH10	101	Q8IZV5
LEICHEISEPRLQNY	STON2	476	Q8WXE9
AVLQVECHPYLAQNE	AKR1A1	181	P14550
PQDYRLAQQVCHAIA	NCAPD2	806	Q15021
ECLIEAVQVYHANPR	CNOT10	376	Q9H9A5
YVAKDPVNQRACHIL	SHC4	306	Q6S5L8
IICDLQPQQVHTFYE	XPO1	621	O14980
YVAKDPINQRACHIL	SHC2	266	P98077
AYILQREIQEPECRH	TRPV1	351	Q8NER1
QFETNDQCRPYHRIL	SLC26A2	41	P50443
PEQIVIHALQCTHYV	STAG2	726	Q8N3U4
FVLETRQPHLCIQYE	REXO5	536	Q96IC2
RQPHLCIQYEVLEAA	REXO5	541	Q96IC2
VEKLPNHRDYQQCAV	STAMBPL1	86	Q96FJ0
HVYCVDNILVRLADP	UAP1L1	251	Q3KQV9
AFVCDIRPEIHENYR	ATP6V1G1	101	O75348
ITHYQQVPLRCNEFE	PLCG1	636	P19174
LNEVEDHIKNYRPQC	SLC12A3	631	P55017
TDRQIEVDIPRCHQY	TBCK	501	Q8TEA7
QEVILRCVPISNHLY	TRBV2	36	A0A1B0GX68
QLRVLEEYSVPCAHA	WDR6	1031	Q9NNW5
HQAEPEAYERRVCFL	PRAG1	1111	Q86YV5
VCLVHPELQSEIYCQ	PLEKHH1	886	Q9ULM0
AEVPIIDRQACEQLY	PRSS48	171	Q7RTY5
IYICEAELFQHPKQQ	ZNF548	111	Q8NEK5
EELAVICANYDIPHI	SEPSECS	236	Q9HD40
TPIILAAHCQEYEIV	TRPC6	221	Q9Y210
VDQREIQHVCLYEIG	TTC39C	346	Q8N584
NNQIEYEHRAPECRL	TET2	1346	Q6N021
IYLQCNLHAPQRELE	WDR87	801	Q6ZQQ6
YVAKDPVNQRACHIL	SHC1	276	P29353
AVNVETHIIKNPYEC	ZNF560	336	Q96MR9
QTVARQTVEHCQYRP	UBR5	1281	O95071
TPIILAAHCQEYEIV	TRPC7	166	Q9HCX4
EPFVLHVQCRQLQDA	TYW3	101	Q6IPR3
YPQAVFLEVDVHQCQ	TXNL1	51	O43396
HAPYVEEDLLIQCRH	KMT2D	1511	O14686
CRHQVEYLGLLENVR	MYO1D	606	O94832
RVCRQAPEERNYHIF	MYO7B	241	Q6PIF6
LQHPALQDEVYCQIL	MYO7B	1701	Q6PIF6